In vivo properties of N-(2-aminoethyl)-5-halogeno-2-pyridinecarboxamide 18F- and 123I-labelled reversible inhibitors of monoamine oxidase B

Nuclear Medicine and Biology

Volumn 25, Issue 1, 1998, Pages 47-52

  Bläuenstein, Peter ^a   Rémy, Nathalie ^a   Buck, Alfred ^b   Ametamey, Simon ^a   Häberli, Marc ^a   Schubiger, P August ^a  

^a PAUL SCHERRER INSTITUTE   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

123I labelling; 18F labelling; Inhibitor; MAO B; Metabolite

Indexed keywords

FLUORINE 18; IODINE 123; LAZABEMIDE; MONOAMINE OXIDASE B INHIBITOR; PICOLINIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; DRUG DETERMINATION; DRUG METABOLISM; DRUG UPTAKE; HUMAN; HUMAN EXPERIMENT; ISOTOPE LABELING; LIPOPHILICITY; NONHUMAN; NORMAL HUMAN; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ADULT; ANIMALS; BRAIN; FLUORINE RADIOISOTOPES; HUMANS; IODINE RADIOISOTOPES; MACACA MULATTA; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; PICOLINIC ACIDS; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0031986267     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8051(97)00143-1     Document Type: Article

References (22)

1. 1. Annan N. and Silverman R. B. (1993) New analogs of N-(2-amino-ethyl)-4-chlorobenzamide (Ro 16-6491): Some of the most potent monoamine oxidase-B inactivators. J. Med. Chem. 36, 3968-3970.
2. 11C]deprenyl. J. Neurochem. 49, 522-527.
3. 125I]-Ro 43-0463, a site specific tracer for MAO-B mapping with autoradiography as well as with SPET. J. Receptor Sign. Transduct. Res. 15, 581-593.
4. 18F]N-(2-aminoethyl)-5-fluoropyridine-2-carboxamide, a potential MAO-B imaging tracer for PET. J. Label. Comp. Radiopharm. 36, 933-945.
5. 123I labelling and evaluation of Ro 43-0463, a SPET tracer for MAO-B imaging. Nucl. Med. Biol. 22, 929-936.
6. 3H]Ro19-6327: A reversible ligand and affinity labelling probe for monoamine oxidase-B. Eur. J. Pharmacol. 162, 457-465.
7. 7. Cesura A. M. and Pletscher A. (1992) The new generation of monoamine oxidase inhibitors. Progr. Drug Res. 38, 171-297.
8. 8. Dixon C. M., Park G. R. and Tarbit M. H. (1994) Characterization of the enzyme responsible for the metabolism of sumatriptan in human liver. Biochem. Pharmacol. 47, 1253-1257.
9. 11C-labelled suicide inactivators and PET. Science 23, 481-485.
10. 10. Guengerich F. P. (1987) Cytochrome P-450 enzymes and drug metabolism. Prog. Drug Metab. 10, 1-54.
11. 11. Huber G. J., Alberto R. A., Bläuenstein P. and Anderegg G. (1989) Functionalized linear tetra-aza ligands for complexing technetium: Potential species for antibody labelling. J. Chem. Soc. Chem. Commun., 879-881.
12. 12. Jossan S. S., Gillberg P.-G., Karlsson I., Gottfries C. G. and Oreland L. (1990) Visualization of brain monoamino oxidase B (MAO-B) in dementia of Alzheimer's type by means of large cryosection autoradiography: A pilot study. J. Neural Transm. 32, 61-65.
13. 13. Karajiannis H. and van de Waterbeemd H. (1995) The prediction of the lipophilicity of peptidomimetics: A comparison between experimental and theoretical lipophilicity values of renin inhibitors and their building blocks. Pharm. Acta Helv. 70, 67-77.
14. 14. Kumlien E., Sherif F., Ge L. and Oreland L. (1995) Platelet and brain GABA-transaminase and monoamine oxidase activities in patients with complex partial seizures. Epilepsy Res. 20, 161-170.
15. 15. LeWitt P. A., Segel S. A., Mistura K. L. and Schork M. A. (1993) Symptomatic anti-Parkinson effects of monoamine oxidase-B inhibition: Comparison of selegiline and lazabemide. Clin. Neuropharm. 16, 332-337.
16. 16. Jakubke H. D., Jeschkeit H., Liebisch H. W., Luckner G. and Parthier B., eds. (1980) Lexikon Biochemie. Verlag Chemie, Weinheim.
17. 17. Oehlke J., Schrötter E., Dove S., Schick H. and Niedrich H. (1983) Darstellung einiger 4-und 5-substituierter Pyridin-2-carbonsäuren als Fusarsäureanaloga. Pharmazie 38, 591-596.
18. 18. Schmidt D. E., Votaw J. R., Kessler R. M. and de Paulis T. (1994) Aromatic and amine substituent effects on the apparent lipophilicities of N-[(2-pyrolidinyl)methyl]-substituted benzamides. J. Pharmacol. Sci. 83, 305-315.
19. 19. Schmidt-Thomé J. and Goebel H. (1951) Über 5-Aminopicolinsäure. Hoppe-Seyler's Z. Physiol. Chem. 288, 237-243.
20. 20. Sladek N. E., Manthey C. L., Maki P. A. and Zhang Z. (1989) Xenobiotic oxidation catalysed by aldehyde dehydrogenases. Drug Metab. Rev. 20, 697-720.
21. 21. Wyss R. and Philipp W. (1990) Determination of the monoamine oxidase B inhibitor Ro 19-6327 in plasma by high-performance liquid chromatography using precolumn derivatisation with fluorescamine and fluorescence detection. J. Chromatogr. 507, 187-198.
22. 22. Youdim M. B. H., Ben-Shachar D. and Riederer P. (1990) The role of monoamino oxidase, iron-melanin interaction, and intracellular calcium in Parkinson's disease. J. Neural Transm. 32, 239-248.